

# Niels Reinmuth

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5922142/publications.pdf>

Version: 2024-02-01

7  
papers

2,230  
citations

1684188

5  
h-index

1720034

7  
g-index

12  
all docs

12  
docs citations

12  
times ranked

3046  
citing authors

#	ARTICLE	IF	CITATIONS
1	Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 924-937.	10.7	1,133
2	Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2020, 6, 661.	7.1	446
3	Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy. <i>Cancer Treatment Reviews</i> , 2016, 45, 7-18.	7.7	354
4	Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions. <i>Cancer Treatment Reviews</i> , 2017, 57, 36-49.	7.7	257
5	PF-06439535 (a Bevacizumab Biosimilar) Compared with Reference Bevacizumab (Avastin®), Both Plus Paclitaxel and Carboplatin, as First-Line Treatment for Advanced Non-Squamous Non-Small-Cell Lung Cancer: A Randomized, Double-Blind Study. <i>BioDrugs</i> , 2019, 33, 555-570.	4.6	36
6	Shall we use steroids when treating patients with lung cancer with checkpoint inhibitors?. <i>European Journal of Cancer</i> , 2021, 145, 255-257.	2.8	1
7	Characteristics of long-term survivors in the CASPIAN trial. , 0, , .		0